Xeltis Advances with EIC's €10 Million Investment
Deal News | Apr 08, 2025 | Ysios Capital
In April 2025, Xeltis, a medical technology firm based in The Netherlands, was selected for a €10 million equity investment from the European Innovation Council (EIC) as part of the EIC STEP Scale-Up call program. As one of only seven companies, Xeltis distinguished itself as the sole life science entity among a cohort aimed at enhancing the EU’s economic and technological competitiveness. The funding is poised to aid Xeltis in commercializing its bioresorbable vascular conduits marked by Nobel Prize-winning chemistry. CEO Eliane Schutte highlighted the uniqueness of Xeltis's offering in the field of vascular surgery. CFO Alexander Goemans indicated that this award would facilitate the commercialization of aXess, a novel regenerative vascular access conduit for dialysis patients. Xeltis is not only recognized for the innovation but also its execution capabilities, receiving the STEP Seal for access to additional funding avenues. The aXess technology promises significant benefits over existing solutions by improving safety and reducing complications. Xeltis's ETR platform has potential beyond hemodialysis, with current pivotal trials in Europe and the US. The firm's investors include Ysios Capital and several other notable entities.
Sectors
- Biotechnology
- Medical Devices
Geography
- The Netherlands – Xeltis is headquartered here and making significant strides in medical technology from this location.
- European Union – The funding and focus are part of an EU initiative to enhance competitiveness and support growth in high-potential companies.
- United States – Xeltis is conducting pivotal trials for its aXess product in the US, indicating geographical relevance.
Industry
- Biotechnology – Xeltis is developing bioresorbable vascular conduits, cutting-edge technologies within the biotech space.
- Medical Devices – Xeltis creates implants for vascular access surgery, directly aligning with the medical device sector.
Financials
- €10 million – The equity investment from the European Innovation Council for Xeltis.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Xeltis | Target | Company | Xeltis is a medtech company advancing bioresorbable vascular conduits. |
| Ysios Capital | Investor | Company | A venture capital firm and existing investor in Xeltis. |
| European Innovation Council (EIC) | Investor | Government | The EIC is the entity providing €10 million to Xeltis as part of the STEP Scale-Up call. |
| Eliane Schutte | Chief Executive Officer | Person | CEO of Xeltis who commented on the significance of the funding. |
| Alexander Goemans | Chief Financial Officer | Person | CFO of Xeltis who discussed the commercial implications of the funding. |